Takeda Official Says Alogliptin Faces Near Three-Year U.S. Delay
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical said a launch of its SYR-322 alogliptin diabetes drug would be delayed by nearly three years after U.S. FDA ordered new trials as a condition for approval. The agency told Takeda in March it would need more data on the drug, leading Takeda earlier this month to delay its plans to seek European approval until 2012. A Takeda public relations executive acknowledged the need to conduct more tests would delay U.S. approval until at least the end of the March, 2012, business year. (Click here for more
You may also be interested in...
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.